A clinical-stage pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments for patients with high unmet medical needs
Our mission is to improve the lives of patients battling severe health conditions including refractory epilepsy, osteoarthritis, Fragile X syndrome, fibromyalgia and peripheral neuropathic pain through synthetic cannabinoid therapeutics formulated for transdermal delivery.
Our team has a proven track record of success in developing novel transdermal products for patients in need.
Our Development Pipeline
We are developing two proprietary products: a transdermal synthetic CBD gel for refractory epilepsy, osteoarthritis and Fragile X syndrome and a novel synthetic THC pro-drug transdermal patch for two pain indications – fibromyalgia and peripheral neuropathic pain.
Learn more about our company and our potential.